{"disease":{"id":"primary-cutaneous-amyloidosis","name":"primary cutaneous amyloidosis"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01164241","title":"Natural History of Severe Allergic Inflammation and Reactions","phase":"","overall_status":"COMPLETED","enrollment_count":945,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT07143864","title":"Efficacy and Safety of Stapokibart for Primary Cutaneous Amyloidosis","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":40,"lead_sponsor_name":"First Affiliated Hospital of Chongqing Medical University","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}